Raji-HER2 cells | ADCC target cells | InvivoGen
Addgene: pcDNA3-HER2-DMVF-181-N
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response | Nature Cancer
Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice | Scientific Reports
PLOS ONE: High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer
Nuclear Y-Box Binding Protein-1, a Predictive Marker of Prognosis, Is Correlated with Expression of HER2/ErbB2 and HER3/ErbB3 in Non-small Cell Lung Cancer - Journal of Thoracic Oncology
Detection of cancer marker Her2 with QD-IgG.(A, C) Fixed breast cancer... | Download Scientific Diagram
HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR | Oncogene
HER2 status in breast Cancer: What does it mean? - Moose and Doc
Aberrant Expression of Novel and Previously Described Cell Membrane Markers in Human Breast Cancer Cell Lines and Tumors | Clinical Cancer Research
Immunohistochemical profiles of ER, PR, HER2 and Ki-67 markers in the... | Download Scientific Diagram
Breast cancer: a new target? | Recherche animale
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy | Scientific Reports
Breast cancer: a new target? | Recherche animale
Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence - Shi - 2019 - Cancer Medicine - Wiley Online Library
HER2 overexpression induced pSTAT3 and stem cell marker expression in... | Download Scientific Diagram
Identification of gene markers for HER2+, Luminal A/B and TNBC. (A)... | Download Scientific Diagram
Cancers | Free Full-Text | HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness | HTML
Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)
Constitutively Activated STAT3 May Be a Predictive Marker for Resistance to Trastuzumab in Patients with HER2 Positive Breast Cancer | ESMO
Mitochondrial MKP1 Is a Target for Therapy-Resistant HER2-Positive Breast Cancer Cells | Cancer Research
STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
